Literature DB >> 11120791

Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC.

N Dalyot-Herman1, O F Bathe, T R Malek.   

Abstract

In the present report, we have studied the potential of naive and activated effector CD8(+) T cells to function as anti-tumor T cells to a solid tumor using OVA-specific T cells from TCR-transgenic OT-I mice. Adoptive transfer of naive OT-I T cells into tumor-bearing syngeneic mice did not inhibit tumor cell growth. The adoptively transferred OT-I T cells did not proliferate in lymphoid tissue of tumor-bearing mice and were not anergized by the tumor. In contrast, adoptive transfer of preactivated OT-I CTL inhibited tumor growth in a dose-dependent manner, indicating that E.G7 was susceptible to immune effector cells. Importantly, naive OT-I T cells proliferated and elicited an anti-tumor response if they were adoptively transferred into normal or CD4-deficient mice that were then vaccinated with GM-CSF-induced bone marrow-derived OVA-pulsed APC. Collectively, these data indicate that even though naive tumor-specific T cells are present at a relatively high fraction they remain ignorant of the tumor and demonstrate that a CD8-mediated anti-tumor response can be induced by Ag-pulsed APC without CD4 T cell help.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120791     DOI: 10.4049/jimmunol.165.12.6731

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Authors:  Ben C Creelan; Scott Antonia; David Noyes; Terri B Hunter; George R Simon; Gerold Bepler; Charles C Williams; Tawee Tanvetyanon; Eric B Haura; Michael J Schell; Alberto Chiappori
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

2.  Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling.

Authors:  Fei Yang; Yinxiang Wei; Zhijian Cai; Lei Yu; Lingling Jiang; Chengyan Zhang; Huanmiao Yan; Qingqing Wang; Xuetao Cao; Tingbo Liang; Jianli Wang
Journal:  Cell Mol Immunol       Date:  2014-04-28       Impact factor: 11.530

3.  The basis of distinctive IL-2- and IL-15-dependent signaling: weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effector-memory cell development.

Authors:  Iris Castro; Aixin Yu; Michael J Dee; Thomas R Malek
Journal:  J Immunol       Date:  2011-10-07       Impact factor: 5.422

4.  Altered homeostasis and development of regulatory T cell subsets represent an IL-2R-dependent risk for diabetes in NOD mice.

Authors:  Connor J Dwyer; Allison L Bayer; Carmen Fotino; Liping Yu; Cecilia Cabello-Kindelan; Natasha C Ward; Kevin H Toomer; Zhibin Chen; Thomas R Malek
Journal:  Sci Signal       Date:  2017-12-19       Impact factor: 8.192

Review 5.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

6.  Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

Authors:  Yanyan Lou; Gang Wang; Gregory Lizée; Grace J Kim; Steven E Finkelstein; Chiguang Feng; Nicholas P Restifo; Patrick Hwu
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

7.  TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression.

Authors:  Maria Giovanna di Bari; M E Christine Lutsiak; Shinji Takai; Sven Mostböck; Benedetto Farsaci; Roshanak Tolouei Semnani; Lalage M Wakefield; Jeffrey Schlom; Helen Sabzevari
Journal:  Cancer Immunol Immunother       Date:  2009-03-25       Impact factor: 6.968

8.  Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.

Authors:  Christina M Ryan; Kevin Staveley-O'Carroll; Todd D Schell
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

9.  Developmental Progression and Interrelationship of Central and Effector Regulatory T Cell Subsets.

Authors:  Kevin H Toomer; Xiaomei Yuan; Jing Yang; Michael J Dee; Aixin Yu; Thomas R Malek
Journal:  J Immunol       Date:  2016-03-23       Impact factor: 5.422

Review 10.  Immunological ignorance of solid tumors.

Authors:  Adrian F Ochsenbein
Journal:  Springer Semin Immunopathol       Date:  2005-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.